Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...155156157158159160161162163164165...10651066»
  • ||||||||||  Ninlaro (ixazomib) / Takeda
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  IFM2014-01: IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic (clinicaltrials.gov) -  Jun 5, 2023   
    P2,  N=26, Terminated, 
    N=70 --> 26 | Trial completion date: Oct 2023 --> Feb 2023 | Not yet recruiting --> Terminated | Trial primary completion date: Oct 2023 --> Dec 2022; Recruitment issue, 26 patients enrolled instead of 70 initially planned
  • ||||||||||  hydrocortisone / Generic mfg., flutamide / Generic mfg.
    Phase classification, Trial completion date, Trial primary completion date, Combination therapy:  Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia (clinicaltrials.gov) -  Jun 5, 2023   
    P4,  N=62, Active, not recruiting, 
    N=70 --> 26 | Trial completion date: Oct 2023 --> Feb 2023 | Not yet recruiting --> Terminated | Trial primary completion date: Oct 2023 --> Dec 2022; Recruitment issue, 26 patients enrolled instead of 70 initially planned Phase classification: P2 --> P4 | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jun 2022
  • ||||||||||  Rybrevant (amivantamab-vmjw) / J&J
    Enrollment open, Trial completion date:  SKIPPirr: Premedication to Reduce Amivantamab Associated Infusion Related Reactions (clinicaltrials.gov) -  Jun 5, 2023   
    P2,  N=120, Recruiting, 
    Phase classification: P2 --> P4 | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jun 2022 Not yet recruiting --> Recruiting | Trial completion date: Jun 2024 --> Dec 2025
  • ||||||||||  prednisolone / Generic mfg.
    Unilateral retinal vasculitis after Covid-19 vaccination: a case report (Exhibition Hall) -  Jun 4, 2023 - Abstract #SOE2023SOE_1152;    
    Symptoms appeared 2 week after recent second dose mRNA Covid-19 vaccination. Anamnesis: patient has Juvenil Idiopathic Artritis (ANA negative), chronic uveitis in right eye with recurrent exacerbation- mild macular and optic disc oedema, posterior synaechiae, epiretinal membrane.
  • ||||||||||  methylprednisolone sodium succinate / Generic mfg.
    SARS-CoV-2 infection, a trigger for multiple sclerosis (Exhibition Hall) -  Jun 4, 2023 - Abstract #SOE2023SOE_937;    
    There is still an uncertainty whether an infection with SARS-CoV-2 in unvaccinated people could precipitate and accelerate the onset of a latent pathology. _x000D_ _x000D_ _x000D_
  • ||||||||||  methylprednisolone sodium succinate / Generic mfg.
    Leber's idiopathic stellate neuroretinitis: case report (Exhibition Hall) -  Jun 4, 2023 - Abstract #SOE2023SOE_936;    
    Patient received 4 days of intravenous methylprednisoloneat 10mg/kg/D for 4 days in a row and an oral relay was started with a progressive degression over 2 weeks...Complementary examinations must be oriented according to the data of the clinical examination. _x000D_ _x000D_ _x000D_
  • ||||||||||  dexamethasone / Generic mfg.
    Preclinical, Journal:  Artesunate alleviates hypoxic-ischemic brain damage in neonatal rats by inhibiting NLRP3 inflammasome activation and inflammatory cytokine secretion (Pubmed Central) -  Jun 3, 2023   
    Methods 7-day-old neonatal SD rats were randomly divided into sham operation group, model group, artesunate 5 mg/kg group, artesunate 10 mg/kg group, artesunate 20 mg/kg group and dexamethasone 6 mg/kg group, with 18 rats in each group...Conclusion Artesunate can improve the neurological function, relieve the brain damage, and alleviate the brain edema in neonatal rats with HIBD. It can protect the HIBD, which may be related to the inhibition of NLRP3 inflammasome activation and reduction of inflammatory cytokine secretion.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal, CINV:  Chemotherapy-induced nausea and vomiting (Pubmed Central) -  Jun 3, 2023   
    It can protect the HIBD, which may be related to the inhibition of NLRP3 inflammasome activation and reduction of inflammatory cytokine secretion. The introduction of high-dose dexamethasone as well as 5?HT3 and NK1 receptor antagonists has led to a
  • ||||||||||  cyclophosphamide / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
    Review, Journal:  Parkinsonism as the presenting manifestation of lupus: A case-based review. (Pubmed Central) -  Jun 2, 2023   
    ISB with levobupivacaine and dexamethasone can provide more effective postoperative pain control after ARCR than ropivacaine and dexamethasone. A high index of suspicion needs to be exercised in cases of SLE presenting with Parkinsonism as adequate immunosuppression translates to near-complete recovery.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Retrospective data, Journal:  Low dose vs high dose tocilizumab in COVID-19 patients with hypoxemic respiratory failure. (Pubmed Central) -  Jun 2, 2023   
    Compared to low dose tocilizumab, the high dose did not provide additional efficacy and mortality benefit but resulted in higher fungal and viral infections. This study illustrates that low dose tocilizumab can be an alternative to high dose during a drug shortage of tocilizumab without compensating for efficacy and safety, conserving resources for more patients.
  • ||||||||||  Atgam (equine anti-thymocyte globulin) / Pfizer
    Enrollment open:  TRIUMPH: TReatment for ImmUne Mediated PathopHysiology (clinicaltrials.gov) -  Jun 2, 2023   
    P2b,  N=163, Recruiting, 
    Trial completion date: May 2023 --> May 2025 | Trial primary completion date: May 2023 --> May 2025 Active, not recruiting --> Recruiting
  • ||||||||||  hydrocortisone / Generic mfg.
    Journal:  Protective Effects of Different Doses of Ginsenoside-Rb1 Experimental Cataract Model that in Chick Embryos. (Pubmed Central) -  Jun 1, 2023   
    Five different experimental groups were formed with 100 SPF fertilized eggs: Control (0.9% NaCl to physiological saline), hydrocortisone hemisuccinate sodium (HC), low dose (HC?+?L-GRb1 (1?mg/kg)), medium dose (HC+)...1?mg/kg and 2.5?mg/kg GRb1 applications show therapeutic properties on the HC-induced cataract model. This effect is more pronounced at 2.5?mg/kg.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Coupling of NIR Spectroscopy and Chemometrics for the Quantification of Dexamethasone in Pharmaceutical Formulations. (Pubmed Central) -  Jun 1, 2023   
    The first, based on the coupling of NIR spectra and Partial Least Squares (PLS) provided good results (root mean square error in prediction (RMSEP) of 720 mg/kg), but the most accurate was the second, a strategy exploiting sequential preprocessing through orthogonalization (SPORT), which led (on the external set of mixtures) to an R of 0.9044, and an RMSEP of 450 mg/kg. Eventually, Variable Importance in Projection (VIP) was applied to interpret the obtained results and determine which spectral regions contribute most to the SPORT model.
  • ||||||||||  Olumiant (baricitinib) / Incyte, Eli Lilly, Actemra IV (tocilizumab) / Roche, JW Pharma, Paxlovid (nirmatrelvir and ritonavir) / Pfizer
    COVID-19 and Other Viral Infections in Patients With Hematologic Malignancies () -  Jun 1, 2023 - Abstract #ASCO2023ASCO_7158;    
    Dexamethasone can be considered on an individual basis, weighing oxygen requirements and patients' underlying disease and their perceived ability to clear infection...We summarize the available evidence regarding viral infections after CAR T-cell therapy. PRACTICAL APPLICATIONS: Patients with blood cancer are at elevated risk of morbidity and mortality from COVID-19.Vaccination remains the most important line of defense against COVID-19, including among patients with blood cancer.Outpatient and inpatient evidence-based treatments are available to decrease the morbidity and mortality of COVID-19 among patients with blood cancer.Viral infections, especially respiratory viruses, are prevalent in the later phase after chimeric antigen receptor (CAR) T-cell therapy, when lymphopenia and hypogammaglobulinemia become common.Mortality after COVID-19 infection in CAR T-cell recipients remains high, and prevention with adequate mask wearing and social distancing and repeated booster doses of mRNA vaccines to maximize T-cell response are part of ongoing consensus recommendations.
  • ||||||||||  Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
    PK/PD data, Preclinical, Journal:  HPLC methods for studying pharmacokinetics of tivozanib and in vitro metabolic interaction with dexamethasone in rat. (Pubmed Central) -  Jun 1, 2023   
    Dexamethasone is commonly used in the management of cancer disease and thus coadministration with tivozanib therapy may cause treatment failure in patients. The simplicity, speed and cost-effectiveness of the reported methods are ideal for supporting in vivo and in vitro tivozanib studies, including drug-drug interaction studies, particularly in bioanalytical labs lacking LC-MS/MS capabilities.
  • ||||||||||  dexamethasone / Generic mfg.
    Trial completion date, Trial primary completion date:  DEXRAR: DEXamethasone in Revision ARthroplasty (clinicaltrials.gov) -  Jun 1, 2023   
    P4,  N=108, Recruiting, 
    Anaesthesiologists might want to consider intravenous dexamethasone for postoperative pain after caesarean delivery under spinal anaesthesia with an intrathecal long-acting opioid. Trial completion date: Dec 2022 --> Dec 2025 | Trial primary completion date: Dec 2021 --> Dec 2024
  • ||||||||||  dexamethasone / Generic mfg.
    Trial completion:  AVS After 1mg DST to Determine Subtype in PA (clinicaltrials.gov) -  Jun 1, 2023   
    P=N/A,  N=110, Completed, 
    Not yet recruiting --> Recruiting Active, not recruiting --> Completed
  • ||||||||||  Pandel (hydrocortisone probutate) / Novartis, Vampex (carbenoxolone gel) / York Pharma
    Journal:  Discovery of novel inhibitor of 11 beta-hydroxysteroid dehydrogenase type 1 using in silico structure-based screening approach for the treatment of type 2 diabetes. (Pubmed Central) -  May 31, 2023   
    The binding energies of hydrocortisone succinate, medroxyprogesterone acetate, testolactone, hydrocortisone cypionate, deoxycorticosterone acetate, and hydrocortisone probutate were lower than that of substrate corticosterone...The docking study revealed that hydrocortisone cypionate has a higher binding affinity than carbenoxolone and its other analogs...These findings indicate the potential use of this FDA approved drug in the treatment of type 2 diabetes. However, validation by in vitro inhibitory studies and clinical trials on type 2 diabetes patients is essential to confirm the current findings.